journal article·2026-07Open access

A self-assembled protein nanocage as a universal influenza vaccine induces enhanced broadly cross-reactive immunity

Jaeyoung Park, Sydney C. Wimberley, Thomas Pho, Mariela R. Rodriguez-Otero, Julie A. Champion

Biomaterials· Volume 330

Abstract

Proteins are an effective platform for vaccine design by enabling multivalent antigen presentation and stabilizing antigen structures to enhance immunogenicity. This study investigates the molecular design and ability to position antigens on self-assembled protein nanocages (SAPNs) as a universal influenza vaccine, incorporating highly conserved nucleoprotein peptides (NP55-69 and NP147-158) as CD4+ and CD8+ T cell antigens alongside hemagglutinin stalk (HrHA) and matrix protein 2 ectodomain (4M2e). The SAPNs display HrHA and 4M2e on their external surface while embedding NP antigens internally. The engineered SAPNs feature a modular design, enabling precise antigen placement and enhanced accessibility through optimized linker length. This nanostructure elicited robust cellular and humoral immune responses in mice, including cross-reactive antibodies and antigen-specific T cell activation. These findings highlight the potential of SAPNs as a versatile platform for universal influenza vaccine development and the role that protein design plays in the spatial organization of self-assembled protein materials and its effect on biomedical function.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · vaccines and immunoinformatics approaches · Influenza Virus Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (94)

Show source-provided references
1. Quadrivalent influenza nanoparticle vaccines induce broad protection10.1038/s41586-021-03365-x ↗
2. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection10.1016/j.cell.2021.01.035 ↗
3. Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals10.1016/j.cell.2024.07.052 ↗
4. Proactive vaccination using multiviral quartet nanocages to elicit broad anti-coronavirus responses10.1038/s41565-024-01655-9 ↗
5. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus10.1016/j.cell.2019.01.046 ↗
6. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-210.1016/j.cell.2020.10.043 ↗
7. Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies10.1039/D1NR03831A ↗
8. Advanced technologies for the development of infectious disease vaccines10.1038/s41573-024-01041-z ↗
9. Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles10.1002/bip.23563 ↗
10. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials10.1016/S0140-6736(20)32014-6 ↗
11. Accurate design of megadalton-scale two-component icosahedral protein complexes10.1126/science.aaf8818 ↗
12. Design of a hyperstable 60-subunit protein icosahedron10.1038/nature18010 ↗
13. Accurate design of co-assembling multi-component protein nanomaterials10.1038/nature13404 ↗
14. Computational design of self-assembling protein nanomaterials with atomic level accuracy10.1126/science.1219364 ↗
15. Evolution and ecology of influenza A viruses10.1128/mr.56.1.152-179.1992 ↗
16. The influenza virus hemagglutinin head evolves faster than the stalk domain10.1038/s41598-018-28706-1 ↗
17. Variation and infectivity neutralization in influenza10.1111/j.1365-2567.2006.02421.x ↗
18. A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein10.1016/j.ebiom.2024.105153 ↗
19. Influenza vaccine effectiveness and progress towards a universal influenza vaccine10.1007/s40265-024-02083-8 ↗
20. Influenza vaccine: a review on current scenario and future prospects10.1186/s43141-023-00581-y ↗
21. The race toward a universal influenza vaccine: front runners and the future directions10.1016/j.antiviral.2022.105505 ↗
22. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults10.1126/scitranslmed.ade4790 ↗
23. Advances in adjuvanted influenza vaccines10.3390/vaccines11081391 ↗
24. Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines10.1038/s41467-024-50087-5 ↗
25. Shaping humoral immunity to vaccines through antigen-displaying nanoparticles10.1016/j.coi.2020.01.007 ↗
26. New vaccine design and delivery technologies10.1093/infdis/jiy745 ↗
27. Protect, modify, deprotect (PMD): a strategy for creating vaccines to elicit antibodies targeting a specific epitope10.1073/pnas.1822062116 ↗
28. Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope10.1016/j.chom.2019.04.003 ↗
29. Glycan masking focuses immune responses to the HIV-1 CD4-Binding site and enhances elicitation of VRC01-Class precursor antibodies10.1016/j.immuni.2018.07.005 ↗
30. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens
31. Altering the immunogenicity of hemagglutinin immunogens by hyperglycosylation and disulfide stabilization10.3389/fimmu.2021.737973 ↗
32. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies10.1038/nature12202 ↗
33. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence10.1038/s41467-019-10262-5 ↗
34. Development of self-assembled protein nanocage spatially functionalized with HA stalk as a broadly cross-reactive influenza vaccine platform10.1021/acsnano.3c07669 ↗
35. Self-assembling cages from coiled-coil peptide modules10.1126/science.1233936 ↗
36. Decorating self-assembled peptide cages with proteins10.1021/acsnano.7b02368 ↗
37. Crystal structure of an isoleucine-zipper trimer10.1038/371080a0 ↗
38. A switch between Two-, Three-, and four-stranded coiled coils in GCN4 leucine zipper mutants10.1126/science.8248779 ↗
39. Designed heterodimerizing leucine zippers with a ranger of pIs and stabilities up to 10−15 M10.1110/ps.39401 ↗
40. Quantifying T cell cross-Reactivity: influenza and coronaviruses10.3390/v13091786 ↗
41. Broad CD8+ T cell cross-recognition of distinct influenza A strains in humans10.1038/s41467-018-07815-5 ↗
42. Human CD8+ T cell cross-reactivity across influenza A, B and C viruses10.1038/s41590-019-0320-6 ↗
43. T cell immunity against influenza: the long way from animal models towards a real-life universal flu vaccine10.3390/v13020199 ↗
44. Investigation of CD4 and CD8 T cell-mediated protection against influenza A virus in a cohort study10.1186/s12916-022-02429-7 ↗
45. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine10.1038/342561a0 ↗
46. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus10.1016/S0264-410X(02)00187-1 ↗
47. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection10.1016/0264-410X(95)00088-I ↗
48. DNA-epitope vaccine provided efficient protection to mice against lethal dose of influenza A virus H1N110.1089/vim.2013.0080 ↗
49. Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus10.1016/j.vetmic.2017.03.004 ↗
50. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines10.1016/j.biomaterials.2010.12.054 ↗
51. Duan · Biol. Med. · 2016 · 89 · 424
52. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo10.1016/j.immuni.2020.08.001 ↗
53. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design10.1016/j.smim.2007.11.007 ↗
54. Dendritic cell migration in health and disease10.1038/nri.2016.116 ↗
55. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns10.1038/nri2868 ↗
56. Effect of antigen structure in subunit vaccine nanoparticles on humoral immune responses10.1021/acsbiomaterials.2c01516 ↗
57. Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro10.2147/IJN.S137222 ↗
58. Effects of engineered nanoparticles on the innate immune system10.1016/j.smim.2017.09.011 ↗
59. Multivalency beats complexity: a study on the cell uptake of carbohydrate functionalized nanocarriers to dendritic cells10.3390/cells9092087 ↗
60. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals10.4049/jimmunol.177.11.7551 ↗
61. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease10.1615/CritRevImmunol.v32.i1.30 ↗
62. Viral infection increases glucocorticoid-induced interleukin-10 production through ERK-mediated phosphorylation of the glucocorticoid receptor in dendritic cells: potential clinical implications10.1371/journal.pone.0063587 ↗
63. Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like receptor signaling10.1089/jir.2006.26.893 ↗
64. Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice10.1073/pnas.1805713115 ↗
65. Monophosphoryl lipid A-adjuvanted nucleoprotein-neuraminidase nanoparticles improve immune protection against divergent influenza viruses10.1016/j.nano.2022.102614 ↗
66. Highly accurate protein structure prediction with AlphaFold10.1038/s41586-021-03819-2 ↗
67. UCSF ChimeraX: tools for structure building and analysis10.1002/pro.4792 ↗
68. Fusion protein linkers: property, design and functionality10.1016/j.addr.2012.09.039 ↗
69. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli10.1073/pnas.85.16.5879 ↗
70. T-cell activation by dendritic cells in the lymph node: lessons from the movies10.1038/nri2379 ↗
71. Regulation of T cell immunity by dendritic cells10.1016/S0092-8674(01)00455-X ↗
72. The role of dendritic cells in T cell activation10.1038/icb.1997.35 ↗
73. Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs10.1002/adhm.201400137 ↗
74. A Scherer, M Salathé, S Bonhoeffer, High epitope expression levels increase competition between T cells, PLoS Comput Biol 2 (8) (2006) e109, doi:10.1371/journal.pcbi.0020109.10.1371/journal.pcbi.0020109 ↗
75. Superactivation of an immune response triggered by oligomerized T cell epitopes10.1073/pnas.94.26.14642 ↗
76. Modulation of immune responses by particle size and shape10.3389/fimmu.2020.607945 ↗
77. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model10.1016/j.ijpharm.2005.03.035 ↗
78. Harnessing nanoparticles for immune modulation10.1016/j.it.2015.05.007 ↗
79. Nanoparticle uptake: the phagocyte problem10.1016/j.nantod.2015.06.006 ↗
80. Effect of micro- and nanoparticle shape on biological processes10.1016/j.jconrel.2021.12.032 ↗
81. Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance10.3389/fbioe.2023.1242126 ↗
82. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics10.1038/s41565-021-00858-8 ↗
83. Macrophage cytokines: involvement in immunity and infectious diseases10.3389/fimmu.2014.00491 ↗
84. Macrophages in immunoregulation and therapeutics10.1038/s41392-023-01452-1 ↗
85. Dendritic cell migration in inflammation and immunity10.1038/s41423-021-00726-4 ↗
86. Macrophages: their untold story in T cell activation and function10.1016/bs.ircmb.2018.07.001 ↗
87. Macrophages direct location-dependent recall of B cell memory to vaccination10.1016/j.cell.2025.04.005 ↗
88. Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses10.1038/s41467-017-02725-4 ↗
89. Multilayer adjuvanted influenza protein nanoparticles improve intranasal delivery and antigen-specific immunity10.1021/acsnano.4c14735 ↗
90. Precision-engineering of subunit vaccine particles for prevention of infectious diseases10.3389/fimmu.2023.1131057 ↗
91. Nanoparticles in subunit vaccines: immunological foundations, categories, and applications10.1002/smll.202407649 ↗
92. Safety assessment of adjuvanted vaccines: methodological considerations10.1080/21645515.2015.1043501 ↗
93. The how’s and what’s of vaccine reactogenicity, npj
94. Endotoxin limits in formulations for preclinical research10.1002/jps.21152 ↗